GlassScriptPhysician profile
Martha R Wafer
NPI 1619179421
$7,208.53
in general payments reported to CMS, 2019-2025
38 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $1,402 · 2021: $1,386 · 2022: $471 · 2023: $712 · 2024: $595 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $859.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $694.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $595.37 | 2019-2024 | Xifaxan |
| Abbvie INC. | $520.27 | 2020-2023 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $448.25 | 2019-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $432.90 | 2019-2023 | Veozah |
| Sumitomo Pharma America, INC. | $429.51 | 2023-2025 | Gemtesa, Myfembree |
| Teva Pharmaceuticals USA, INC. | $373.88 | 2019-2021 | |
| Pfizer INC. | $349.69 | 2019-2023 | |
| Amgen INC. | $343.98 | 2019-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $317.49 | 2019-2020 | |
| Indivior INC. | $213.68 | 2019-2025 | Sublocade |
| Amarin Pharma, INC. | $208.18 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $199.63 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $158.28 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Wafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.